Wan Hejia, Qian Wenli, Wei Bingqi, Tian Kaiyue, Chen Ziyi, Zhang Jiong, Chen Fang
School of Medicine, Henan University of Chinese Medicine, Zhengzhou, China.
School of Nursing, Henan University of Chinese Medicine, Zhengzhou, China.
Front Neurosci. 2024 Nov 26;18:1499025. doi: 10.3389/fnins.2024.1499025. eCollection 2024.
OBJECTIVE: To learn more about gene editing and ALS, and to provide a comprehensive view of gene editing for further treatment of amyotrophic lateral sclerosis. METHODS: We searched 1981 records from Web of Science core collection and Pubmed, Scopus, of which 1,292 records were obtained after exclusion. We then scientifically and metrologically analyzed these records for spatial and temporal distribution, author distribution, subject categories, subject distribution, references, and keywords using R, software CiteSpace and VOSviewer. RESULTS: Our analysis provides basic information about research in the field, suggests that the field has stabilized over the past decade, and identifies potential partners for interested researchers. Current research in this area is focused on inflammatory mechanisms, immune mechanisms, related diseases, and associated cytokines in ALS. CONCLUSION: RNA Editing, Antisense Bligonucleotide, and Glycine Receptor are cutting-edge research topics in this field, which is undergoing rapid development. We hope that this work will provide new ideas for advancing the scientific research and clinical application of ALS.
目的:更深入了解基因编辑与肌萎缩侧索硬化症(ALS),并全面审视基因编辑在肌萎缩侧索硬化症后续治疗中的应用。 方法:我们在科学引文索引核心合集、PubMed及Scopus数据库中检索了1981条记录,排除后共获得1292条记录。随后,我们使用R软件、CiteSpace软件和VOSviewer对这些记录进行科学计量分析,内容包括时空分布、作者分布、学科类别、主题分布、参考文献及关键词。 结果:我们的分析提供了该领域研究的基础信息,表明该领域在过去十年已趋于稳定,并为感兴趣的研究人员确定了潜在合作伙伴。目前该领域的研究集中在肌萎缩侧索硬化症的炎症机制、免疫机制、相关疾病及相关细胞因子。 结论:RNA编辑、反义寡核苷酸及甘氨酸受体是该领域的前沿研究课题,该领域正在迅速发展。我们希望这项工作能为推进肌萎缩侧索硬化症的科研及临床应用提供新思路。
Front Neurosci. 2024-11-26
Front Immunol. 2022
Front Physiol. 2024-6-11
Front Immunol. 2023
Front Biosci (Landmark Ed). 2022-8-31
J Multidiscip Healthc. 2024-10-24
Front Bioeng Biotechnol. 2023-3-9
Amyotroph Lateral Scler Frontotemporal Degener. 2023-8
Nat Rev Drug Discov. 2023-3